Paul Bhar - ImmunityBio, Inc | 人才画像

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Karim Chamie,Sam S. Chang,Eugene V. Kramolowsky,Mark L. Gonzalgo,Megan Huang,Paul Bhar,Patricia Spilman,Lennie Sender,Sandeep K. Reddy,Patrick Soon-Shiong

UROLOGY PRACTICEno. 2 (2024): 367-375

引用2浏览0WOS引用

AI-driven image-based microbiome analysis reveals correlation of higher pretreatment microbiome level with complete response in QUILT 3032 trial patients

Mustafa I. Jaber,Kamil Wnuk,Patricia Spilman,Bing Song, David Trianni,Megan Huang,Paul Bhar,Patrick Soon-Shiong,Sandeep Reddy

CANCER PREVENTION RESEARCH（2022）

引用0浏览0引用

Abstract A008: AI-driven Image-Based Microbiome Analysis Reveals Correlation of Higher Pre-Treatment Microbiome Level with Complete Response in QUILT 3032 Trial Patients

Mustafa I. Jaber,Kamil Wnuk,Patricia Spilman,Bing Song, David Trianni,Megan Huang,Paul Bhar,Patrick Soon-Shiong,Sandeep Reddy

Cancer Prevention Research（2022）

引用0浏览0引用

Phase 2 Quilt 88 Trial of DAMP Inducers Combined with IL15 Superagonist, N-803, and Anti–pd-L1 NK Cell Therapy More Than Doubles Historical Overall Survival in Patients with Third- to Sixth-Line Advanced Pancreatic Cancer

Tara Elisabeth Seery,Chaitali Singh Nangia,Heidi Ann McKean,Paul Bhar,Leonard S. Sender,Sandeep K. Reddy,Patrick Soon Shiong

Journal of Clinical Oncology（2022）

引用4浏览0引用

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

NEJM evidenceno. 1 (2022): EVIDoa2200167-EVIDoa2200167

引用44浏览0WOS引用

Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors (CPI)

John M. Wrangle,Mark M. Awad,Firas Benyamine Badin,Mark P. Rubinstein,Paul Bhar,Chad Garner,Sandeep K. Reddy,Patrick Soon-Shiong

Journal of Clinical Oncology（2021）

引用23浏览0引用

Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 with BCG in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS) Patients

Karim Chamie,Sam Chang,Mark L. Gonzalgo,Eugene Kramolowsky,Wade J. Sexton,Sandeep K. Reddy,Paul Bhar,Chad Garner,Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用30浏览0引用

PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS

Karim Chamie,Sam Chang,Mark Gonzalgo,Eugene Kramolowski,Sandeep Reddy,Paul Bhar,Patrick Soon-Shiong,Chad Garner

Journal of Urology（2021）

引用1浏览0引用

Nab-Paclitaxel for First-Line Treatment of Patients with Metastatic Breast Cancer and Poor Prognostic Factors: a Retrospective Analysis

Joyce O’Shaughnessy,William J. Gradishar,Paul Bhar,Jose Iglesias

Breast Cancer Research and Treatment（2013）

引用56浏览0WOS引用

Weekly Nab-Paclitaxel in Combination with Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin As First-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Final Results of A Phase Iii Trial

Mark A. Socinski,Igor Bondarenko,Nina A. Karaseva, Anatoly M. Makhson,Igor Vynnychenko,Isamu Okamoto,Jeremy K. Hon,Vera Hirsh,Paul Bhar,Hui Zhang,Jose L. Iglesias,Markus F. Renschler

JOURNAL OF CLINICAL ONCOLOGY（2012）

引用739浏览0WOS引用

739

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn